A
Andrew G. Robinson
Researcher at Queen's University
Publications - 71
Citations - 10218
Andrew G. Robinson is an academic researcher from Queen's University. The author has contributed to research in topics: Pembrolizumab & Lung cancer. The author has an hindex of 19, co-authored 59 publications receiving 6984 citations. Previous affiliations of Andrew G. Robinson include Kingston General Hospital & Sunnybrook Health Sciences Centre.
Papers
More filters
Journal ArticleDOI
Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
Martin Reck,Delvys Rodriguez-Abreu,Andrew G. Robinson,Rina Hui,Tibor Csőszi,Andrea Fülöp,Maya Gottfried,Nir Peled,Ali Tafreshi,Sinead Cuffe,Mary O'Brien,Suman Rao,Katsuyuki Hotta,Melanie A. Leiby,Gregory M. Lubiniecki,Yue Shentu,Reshma A. Rangwala,Julie R. Brahmer +17 more
TL;DR: Pembrolizumab is a humanized monoclonal antibody against programmed death 1 (PD-1) that has antitumor activity in advanced non-small-cell lung cancer (NSCLC), with increased activity in tumors that express PD-L1 as mentioned in this paper.
Journal ArticleDOI
Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater
Martin Reck,Delvys Rodriguez-Abreu,Andrew G. Robinson,Rina Hui,Tibor Csoszi,Andrea Fülöp,Maya Gottfried,Nir Peled,Ali Tafreshi,Sinead Cuffe,Mary O'Brien,Suman Rao,Katsuyuki Hotta,Kristel Vandormael,Antonio Riccio,J. Yang,M. Catherine Pietanza,Julie R. Brahmer +17 more
TL;DR: With prolonged follow-up, first-line pembrolizumab monotherapy continues to demonstrate an OS benefit over chemotherapy in patients with previously untreated, advanced NSCLC without EGFR/ALK aberrations, despite crossover from the control arm to pembrolezumab as subsequent therapy.
Journal ArticleDOI
Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score >= 50%
Martin Reck,Delvys Rodriguez-Abreu,Andrew G. Robinson,Rina Hui,Tibor Csőszi,Andrea Fülöp,Maya Gottfried,Nir Peled,Ali Tafreshi,Sinead Cuffe,Mary O'Brien,Suman Rao,Katsuyuki Hotta,Ticiana A. Leal,Jonathan W. Riess,Erin Jensen,Bin Zhao,M. Catherine Pietanza,Julie R. Brahmer +18 more
TL;DR: The first 5-year follow-up of any first-line phase III immunotherapy trial for non-small-cell lung cancer (NSCLC) was reported in this article.
Journal ArticleDOI
A Randomized, Placebo-Controlled Trial of Pembrolizumab Plus Chemotherapy in Patients With Metastatic Squamous NSCLC: Protocol-Specified Final Analysis of KEYNOTE-407
Luis Paz-Ares,David Vicente,Ali Tafreshi,Andrew G. Robinson,Hector Soto Parra,Julien Mazieres,Barbara Hermes,Irfan Cicin,Balazs Medgyasszay,Jerónimo Rodríguez-Cid,Isamu Okamoto,Sung Sook Lee,Rodryg Ramlau,Vladimir Vladimirov,Ying Cheng,Xuan Deng,Ying Zhang,Tuba Bas,Bilal Piperdi,Balazs Halmos +19 more
TL;DR: The PFS-2 outcomes support pembrolizumab plus chemotherapy as a standard first-line treatment in patients with metastatic squamous NSCLC.
Journal ArticleDOI
Therapy for Stage IV Non–Small-Cell Lung Cancer Without Driver Alterations: ASCO and OH (CCO) Joint Guideline Update
Nasser H. Hanna,Bryan J. Schneider,Sarah Temin,Sherman Baker,Julie R. Brahmer,Peter M. Ellis,Laurie E. Gaspar,Laurie E. Gaspar,Rami Y. Haddad,Paul J. Hesketh,Dharamvir Jain,Ishmael Jaiyesimi,David H. Johnson,Natasha B. Leighl,Tanyanika Phillips,Gregory J. Riely,Andrew G. Robinson,Rafael Rosell,Joan H. Schiller,Navneet Singh,David R. Spigel,Janis O. Stabler,Joan Tashbar,Gregory A. Masters +23 more
TL;DR: This guideline update reflects changes in evidence since the previous guideline update and is conditional on the basis of histology, PD-L1 status, and/or the presence of contraindications.